CSAClinical-Stage Asset Intelligence
Catalyst calendar Get the data
Home / DAN (DAN) / pegaspargase
Forward catalyst · DAN

pegaspargase

Sponsor DAN · listed as DAN

READOUT Phase 2;Phase 3 Confidence: medium Source: clinicaltrials

pegaspargase is a clinical-stage drug asset sponsored by DAN, listed as DAN. CSA tracks 2 forward catalysts for it — the nearest is a readout expected Sep 30, 2026 (day precision, medium confidence), tied to trial NCT03117751. The asset is in Phase 2;Phase 3 and currently active not recruiting, studied in Acute Lymphoblastic Leukemia. It appears across 3 tracked trials in the CSA sample.

Next catalyst

Event typeREADOUT
Expected date2026-09-30
As disclosedSep 30, 2026
Date precisionday
Confidencemedium
Verify at source →

Trial & sponsor

Trial (NCT)NCT03117751
PhasePHASE2;PHASE3
StatusACTIVE_NOT_RECRUITING
Lead sponsorSt. Jude Children's Research Hospital
Listed asDAN
Condition(s)Acute Lymphoblastic Leukemia; Acute Lymphoblastic Lymphoma

All tracked catalysts for pegaspargase

DateEventConfidenceTrial
2026-09-30READOUTmediumNCT03117751
2026-11-30READOUTmediumNCT03020030
!

Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.

This is one row of the free CSA sample. The full snapshot carries 2,103 forward catalysts across 139 listed sponsors.

Get the full dataset — $499 →   More DAN catalysts